Evaluation of complete surgical staging with pelvic and para-aortic lymphadenectomy and paclitaxel plus carboplatin chemotherapy for improvement of survival in stage i ovarian clear cell carcinoma
The aim was to determine the benefits of lymphadenectomy and paclitaxel plus carboplatin chemotherapy for stage I ovarian clear cell carcinoma (defined as intra-abdominal disease confined to the ovaries). Twenty patients with stage I pure clear cell carcinoma of the ovary diagnosed between 1991 and...
Gespeichert in:
| Veröffentlicht in: | Gynecologic oncology 2003-03, Vol.88 (3), p.394-399 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 399 |
|---|---|
| container_issue | 3 |
| container_start_page | 394 |
| container_title | Gynecologic oncology |
| container_volume | 88 |
| creator | Ho, Chih-Ming Chien, Tsai-Yen Shih, Bor-Yuan Huang, Shih-Hung |
| description | The aim was to determine the benefits of lymphadenectomy and paclitaxel plus carboplatin chemotherapy for stage I ovarian clear cell carcinoma (defined as intra-abdominal disease confined to the ovaries).
Twenty patients with stage I pure clear cell carcinoma of the ovary diagnosed between 1991 and 2001 were divided into two groups: Group A (12 patients, 1997–2001) underwent complete surgical staging including bilateral salpingo-oophorectomy, hysterectomy, omentectomy, and pelvic and para-aortic lymphadenectomy, followed by paclitaxel and carboplatin chemotherapy. Group B (8 patients, 1991–1996) underwent bilateral salpingo-oophorectomy, hysterectomy, and omentectomy without lymphadenectomy, followed by cisplatin-based chemotherapy. The survival of the two groups was compared. The clinical characteristics of the two groups were evaluated for age distribution, grade, substage, preoperative CA-125, presence or absence of endometriosis, and maximal tumor diameter.
The estimated 4-year survival rate was 76.9%. The clinical characteristics of the two groups were similar, except for lymphadenectomy and regimen of chemotherapy. With a median follow-up of 36 months (range: 11–130 months), one of 12 patients in Group A had recurrence in comparison with 6 of 8 patients in Group B (
P = 0.004). The estimated 3-year recurrence-free survival and 4-year overall survival for Group A was significantly greater than that for Group B (91.7 vs 33.3%,
P = 0.014; 100 vs 50%,
P = 0.014). Median time to recurrence was 8 months.
Complete surgical staging, including pelvic and para-aortic lymphadenectomy and paclitaxel plus carboplatin chemotherapy, appeared to be capable of improving survival of patients with stage I ovarian clear cell carcinoma. |
| doi_str_mv | 10.1016/S0090-8258(02)00156-7 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73109085</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0090825802001567</els_id><sourcerecordid>73109085</sourcerecordid><originalsourceid>FETCH-LOGICAL-c391t-cc8065ba9bd54e159c79c1223e092acd0f3fd136d81d6a28e2c3ad0c89402cfb3</originalsourceid><addsrcrecordid>eNqFkc2O0zAURi0EYjqFRwB5AxoWgWunSZPVCI2GH2kkFsDaurVvWiMnDrYT6PvxYDjTilmysiyf6-_TPYy9EPBWgKjffQVooWhk1VyBfAMgqrrYPmIrAW1V1E3VPmarf8gFu4zxBwCUIORTdiFkvcmIXLE_tzO6CZP1A_cd174fHSXicQp7q9HxmHBvhz3_ZdOBj-RmqzkOho8YsEAfUr67Yz8e0NBAOvn-eH7Xzib8TY6PbopcY9j50eWkgesD9T4dKOB45J0P3PZj8DP1NKSlRQ6fbe7FM7vkE7fczxgs5llHGLgm55YvtR18j8_Ykw5dpOfnc82-f7j9dvOpuPvy8fPN-7tCl61IhdYN1NUO252pNiSqVm9bLaQsCVqJ2kBXdkaUtWmEqVE2JHWJBnTTbkDqbleu2evTv7ntz4liUr2NSxUcyE9Rbcu8fWiqDFYnUAcfY6BOjcH2GI5KgFr0qXt9anGjQKp7fXl8zV6eA6ZdT-Zh6uwrA6_OAMZspws4aBsfuE3diArqzF2fOMrrmC0FFbWlQZOxIUtSxtv_VPkLJOa9ZQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>73109085</pqid></control><display><type>article</type><title>Evaluation of complete surgical staging with pelvic and para-aortic lymphadenectomy and paclitaxel plus carboplatin chemotherapy for improvement of survival in stage i ovarian clear cell carcinoma</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Ho, Chih-Ming ; Chien, Tsai-Yen ; Shih, Bor-Yuan ; Huang, Shih-Hung</creator><creatorcontrib>Ho, Chih-Ming ; Chien, Tsai-Yen ; Shih, Bor-Yuan ; Huang, Shih-Hung</creatorcontrib><description>The aim was to determine the benefits of lymphadenectomy and paclitaxel plus carboplatin chemotherapy for stage I ovarian clear cell carcinoma (defined as intra-abdominal disease confined to the ovaries).
Twenty patients with stage I pure clear cell carcinoma of the ovary diagnosed between 1991 and 2001 were divided into two groups: Group A (12 patients, 1997–2001) underwent complete surgical staging including bilateral salpingo-oophorectomy, hysterectomy, omentectomy, and pelvic and para-aortic lymphadenectomy, followed by paclitaxel and carboplatin chemotherapy. Group B (8 patients, 1991–1996) underwent bilateral salpingo-oophorectomy, hysterectomy, and omentectomy without lymphadenectomy, followed by cisplatin-based chemotherapy. The survival of the two groups was compared. The clinical characteristics of the two groups were evaluated for age distribution, grade, substage, preoperative CA-125, presence or absence of endometriosis, and maximal tumor diameter.
The estimated 4-year survival rate was 76.9%. The clinical characteristics of the two groups were similar, except for lymphadenectomy and regimen of chemotherapy. With a median follow-up of 36 months (range: 11–130 months), one of 12 patients in Group A had recurrence in comparison with 6 of 8 patients in Group B (
P = 0.004). The estimated 3-year recurrence-free survival and 4-year overall survival for Group A was significantly greater than that for Group B (91.7 vs 33.3%,
P = 0.014; 100 vs 50%,
P = 0.014). Median time to recurrence was 8 months.
Complete surgical staging, including pelvic and para-aortic lymphadenectomy and paclitaxel plus carboplatin chemotherapy, appeared to be capable of improving survival of patients with stage I ovarian clear cell carcinoma.</description><identifier>ISSN: 0090-8258</identifier><identifier>EISSN: 1095-6859</identifier><identifier>DOI: 10.1016/S0090-8258(02)00156-7</identifier><identifier>PMID: 12648592</identifier><identifier>CODEN: GYNOA3</identifier><language>eng</language><publisher>San Diego, CA: Elsevier Inc</publisher><subject>Adenocarcinoma, Clear Cell - drug therapy ; Adenocarcinoma, Clear Cell - pathology ; Adenocarcinoma, Clear Cell - surgery ; Adult ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Aorta ; Biological and medical sciences ; Carboplatin - administration & dosage ; Chemotherapy ; Clear cell carcinoma ; Combined Modality Therapy ; Combined treatment ; Female ; Female genital diseases ; Gynecology. Andrology. Obstetrics ; Humans ; Lymph Node Excision ; Lymph Nodes - pathology ; Lymph Nodes - surgery ; Lymphadenectomy ; Medical sciences ; Middle Aged ; Neoplasm Staging ; Ovarian cancer ; Ovarian Neoplasms - drug therapy ; Ovarian Neoplasms - pathology ; Ovarian Neoplasms - surgery ; Paclitaxel - administration & dosage ; Pelvis ; Survival Rate ; Treatment. General aspects ; Tropical medicine ; Tumors</subject><ispartof>Gynecologic oncology, 2003-03, Vol.88 (3), p.394-399</ispartof><rights>2003 Elsevier Science (USA)</rights><rights>2003 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c391t-cc8065ba9bd54e159c79c1223e092acd0f3fd136d81d6a28e2c3ad0c89402cfb3</citedby><cites>FETCH-LOGICAL-c391t-cc8065ba9bd54e159c79c1223e092acd0f3fd136d81d6a28e2c3ad0c89402cfb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0090825802001567$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14681506$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12648592$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ho, Chih-Ming</creatorcontrib><creatorcontrib>Chien, Tsai-Yen</creatorcontrib><creatorcontrib>Shih, Bor-Yuan</creatorcontrib><creatorcontrib>Huang, Shih-Hung</creatorcontrib><title>Evaluation of complete surgical staging with pelvic and para-aortic lymphadenectomy and paclitaxel plus carboplatin chemotherapy for improvement of survival in stage i ovarian clear cell carcinoma</title><title>Gynecologic oncology</title><addtitle>Gynecol Oncol</addtitle><description>The aim was to determine the benefits of lymphadenectomy and paclitaxel plus carboplatin chemotherapy for stage I ovarian clear cell carcinoma (defined as intra-abdominal disease confined to the ovaries).
Twenty patients with stage I pure clear cell carcinoma of the ovary diagnosed between 1991 and 2001 were divided into two groups: Group A (12 patients, 1997–2001) underwent complete surgical staging including bilateral salpingo-oophorectomy, hysterectomy, omentectomy, and pelvic and para-aortic lymphadenectomy, followed by paclitaxel and carboplatin chemotherapy. Group B (8 patients, 1991–1996) underwent bilateral salpingo-oophorectomy, hysterectomy, and omentectomy without lymphadenectomy, followed by cisplatin-based chemotherapy. The survival of the two groups was compared. The clinical characteristics of the two groups were evaluated for age distribution, grade, substage, preoperative CA-125, presence or absence of endometriosis, and maximal tumor diameter.
The estimated 4-year survival rate was 76.9%. The clinical characteristics of the two groups were similar, except for lymphadenectomy and regimen of chemotherapy. With a median follow-up of 36 months (range: 11–130 months), one of 12 patients in Group A had recurrence in comparison with 6 of 8 patients in Group B (
P = 0.004). The estimated 3-year recurrence-free survival and 4-year overall survival for Group A was significantly greater than that for Group B (91.7 vs 33.3%,
P = 0.014; 100 vs 50%,
P = 0.014). Median time to recurrence was 8 months.
Complete surgical staging, including pelvic and para-aortic lymphadenectomy and paclitaxel plus carboplatin chemotherapy, appeared to be capable of improving survival of patients with stage I ovarian clear cell carcinoma.</description><subject>Adenocarcinoma, Clear Cell - drug therapy</subject><subject>Adenocarcinoma, Clear Cell - pathology</subject><subject>Adenocarcinoma, Clear Cell - surgery</subject><subject>Adult</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Aorta</subject><subject>Biological and medical sciences</subject><subject>Carboplatin - administration & dosage</subject><subject>Chemotherapy</subject><subject>Clear cell carcinoma</subject><subject>Combined Modality Therapy</subject><subject>Combined treatment</subject><subject>Female</subject><subject>Female genital diseases</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Lymph Node Excision</subject><subject>Lymph Nodes - pathology</subject><subject>Lymph Nodes - surgery</subject><subject>Lymphadenectomy</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neoplasm Staging</subject><subject>Ovarian cancer</subject><subject>Ovarian Neoplasms - drug therapy</subject><subject>Ovarian Neoplasms - pathology</subject><subject>Ovarian Neoplasms - surgery</subject><subject>Paclitaxel - administration & dosage</subject><subject>Pelvis</subject><subject>Survival Rate</subject><subject>Treatment. General aspects</subject><subject>Tropical medicine</subject><subject>Tumors</subject><issn>0090-8258</issn><issn>1095-6859</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc2O0zAURi0EYjqFRwB5AxoWgWunSZPVCI2GH2kkFsDaurVvWiMnDrYT6PvxYDjTilmysiyf6-_TPYy9EPBWgKjffQVooWhk1VyBfAMgqrrYPmIrAW1V1E3VPmarf8gFu4zxBwCUIORTdiFkvcmIXLE_tzO6CZP1A_cd174fHSXicQp7q9HxmHBvhz3_ZdOBj-RmqzkOho8YsEAfUr67Yz8e0NBAOvn-eH7Xzib8TY6PbopcY9j50eWkgesD9T4dKOB45J0P3PZj8DP1NKSlRQ6fbe7FM7vkE7fczxgs5llHGLgm55YvtR18j8_Ykw5dpOfnc82-f7j9dvOpuPvy8fPN-7tCl61IhdYN1NUO252pNiSqVm9bLaQsCVqJ2kBXdkaUtWmEqVE2JHWJBnTTbkDqbleu2evTv7ntz4liUr2NSxUcyE9Rbcu8fWiqDFYnUAcfY6BOjcH2GI5KgFr0qXt9anGjQKp7fXl8zV6eA6ZdT-Zh6uwrA6_OAMZspws4aBsfuE3diArqzF2fOMrrmC0FFbWlQZOxIUtSxtv_VPkLJOa9ZQ</recordid><startdate>20030301</startdate><enddate>20030301</enddate><creator>Ho, Chih-Ming</creator><creator>Chien, Tsai-Yen</creator><creator>Shih, Bor-Yuan</creator><creator>Huang, Shih-Hung</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20030301</creationdate><title>Evaluation of complete surgical staging with pelvic and para-aortic lymphadenectomy and paclitaxel plus carboplatin chemotherapy for improvement of survival in stage i ovarian clear cell carcinoma</title><author>Ho, Chih-Ming ; Chien, Tsai-Yen ; Shih, Bor-Yuan ; Huang, Shih-Hung</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c391t-cc8065ba9bd54e159c79c1223e092acd0f3fd136d81d6a28e2c3ad0c89402cfb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Adenocarcinoma, Clear Cell - drug therapy</topic><topic>Adenocarcinoma, Clear Cell - pathology</topic><topic>Adenocarcinoma, Clear Cell - surgery</topic><topic>Adult</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Aorta</topic><topic>Biological and medical sciences</topic><topic>Carboplatin - administration & dosage</topic><topic>Chemotherapy</topic><topic>Clear cell carcinoma</topic><topic>Combined Modality Therapy</topic><topic>Combined treatment</topic><topic>Female</topic><topic>Female genital diseases</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Lymph Node Excision</topic><topic>Lymph Nodes - pathology</topic><topic>Lymph Nodes - surgery</topic><topic>Lymphadenectomy</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neoplasm Staging</topic><topic>Ovarian cancer</topic><topic>Ovarian Neoplasms - drug therapy</topic><topic>Ovarian Neoplasms - pathology</topic><topic>Ovarian Neoplasms - surgery</topic><topic>Paclitaxel - administration & dosage</topic><topic>Pelvis</topic><topic>Survival Rate</topic><topic>Treatment. General aspects</topic><topic>Tropical medicine</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ho, Chih-Ming</creatorcontrib><creatorcontrib>Chien, Tsai-Yen</creatorcontrib><creatorcontrib>Shih, Bor-Yuan</creatorcontrib><creatorcontrib>Huang, Shih-Hung</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Gynecologic oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ho, Chih-Ming</au><au>Chien, Tsai-Yen</au><au>Shih, Bor-Yuan</au><au>Huang, Shih-Hung</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation of complete surgical staging with pelvic and para-aortic lymphadenectomy and paclitaxel plus carboplatin chemotherapy for improvement of survival in stage i ovarian clear cell carcinoma</atitle><jtitle>Gynecologic oncology</jtitle><addtitle>Gynecol Oncol</addtitle><date>2003-03-01</date><risdate>2003</risdate><volume>88</volume><issue>3</issue><spage>394</spage><epage>399</epage><pages>394-399</pages><issn>0090-8258</issn><eissn>1095-6859</eissn><coden>GYNOA3</coden><abstract>The aim was to determine the benefits of lymphadenectomy and paclitaxel plus carboplatin chemotherapy for stage I ovarian clear cell carcinoma (defined as intra-abdominal disease confined to the ovaries).
Twenty patients with stage I pure clear cell carcinoma of the ovary diagnosed between 1991 and 2001 were divided into two groups: Group A (12 patients, 1997–2001) underwent complete surgical staging including bilateral salpingo-oophorectomy, hysterectomy, omentectomy, and pelvic and para-aortic lymphadenectomy, followed by paclitaxel and carboplatin chemotherapy. Group B (8 patients, 1991–1996) underwent bilateral salpingo-oophorectomy, hysterectomy, and omentectomy without lymphadenectomy, followed by cisplatin-based chemotherapy. The survival of the two groups was compared. The clinical characteristics of the two groups were evaluated for age distribution, grade, substage, preoperative CA-125, presence or absence of endometriosis, and maximal tumor diameter.
The estimated 4-year survival rate was 76.9%. The clinical characteristics of the two groups were similar, except for lymphadenectomy and regimen of chemotherapy. With a median follow-up of 36 months (range: 11–130 months), one of 12 patients in Group A had recurrence in comparison with 6 of 8 patients in Group B (
P = 0.004). The estimated 3-year recurrence-free survival and 4-year overall survival for Group A was significantly greater than that for Group B (91.7 vs 33.3%,
P = 0.014; 100 vs 50%,
P = 0.014). Median time to recurrence was 8 months.
Complete surgical staging, including pelvic and para-aortic lymphadenectomy and paclitaxel plus carboplatin chemotherapy, appeared to be capable of improving survival of patients with stage I ovarian clear cell carcinoma.</abstract><cop>San Diego, CA</cop><pub>Elsevier Inc</pub><pmid>12648592</pmid><doi>10.1016/S0090-8258(02)00156-7</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0090-8258 |
| ispartof | Gynecologic oncology, 2003-03, Vol.88 (3), p.394-399 |
| issn | 0090-8258 1095-6859 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_73109085 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adenocarcinoma, Clear Cell - drug therapy Adenocarcinoma, Clear Cell - pathology Adenocarcinoma, Clear Cell - surgery Adult Antineoplastic Combined Chemotherapy Protocols - therapeutic use Aorta Biological and medical sciences Carboplatin - administration & dosage Chemotherapy Clear cell carcinoma Combined Modality Therapy Combined treatment Female Female genital diseases Gynecology. Andrology. Obstetrics Humans Lymph Node Excision Lymph Nodes - pathology Lymph Nodes - surgery Lymphadenectomy Medical sciences Middle Aged Neoplasm Staging Ovarian cancer Ovarian Neoplasms - drug therapy Ovarian Neoplasms - pathology Ovarian Neoplasms - surgery Paclitaxel - administration & dosage Pelvis Survival Rate Treatment. General aspects Tropical medicine Tumors |
| title | Evaluation of complete surgical staging with pelvic and para-aortic lymphadenectomy and paclitaxel plus carboplatin chemotherapy for improvement of survival in stage i ovarian clear cell carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T03%3A19%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20of%20complete%20surgical%20staging%20with%20pelvic%20and%20para-aortic%20lymphadenectomy%20and%20paclitaxel%20plus%20carboplatin%20chemotherapy%20for%20improvement%20of%20survival%20in%20stage%20i%20ovarian%20clear%20cell%20carcinoma&rft.jtitle=Gynecologic%20oncology&rft.au=Ho,%20Chih-Ming&rft.date=2003-03-01&rft.volume=88&rft.issue=3&rft.spage=394&rft.epage=399&rft.pages=394-399&rft.issn=0090-8258&rft.eissn=1095-6859&rft.coden=GYNOA3&rft_id=info:doi/10.1016/S0090-8258(02)00156-7&rft_dat=%3Cproquest_cross%3E73109085%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=73109085&rft_id=info:pmid/12648592&rft_els_id=S0090825802001567&rfr_iscdi=true |